We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05540873
Recruitment Status : Recruiting
First Posted : September 15, 2022
Last Update Posted : January 6, 2023
Information provided by (Responsible Party):

Brief Summary:

This is a phase I study to evaluate the safety and tolerability of IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell in patients with Refractory or Recurrent Malignant Glioma and to evaluate the changes of AE incidence.

And this study have to long term follow-up.

Condition or disease Intervention/treatment Phase
Recurrent Malignant Glioma Drug: YYB-103 Phase 1

Detailed Description:

This is a single-center, single-arm, open-label phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts. The objectives of this study is to assess the safety and tolerability after administration of YYB-103 (IL13Rα2 targeted CAR-T cell) in patients with malignant glioma.

YYB-103 is designed to target cancer cells expressing IL13Rα2 in cell surface. Only those subjects who are expressing IL13Rα2 and satisfy the inclusion and exclusion criteria will receive IV infusion of YYB-103.

Long term follow-up study is evaluate the safety and exploratory efficacy of IP for 15 years from the date of IP administration in patients with malignant glioma refractory or recurrent to standard therapy who participated in this study.

Subjects who participated in the Phase 1 study and received YYB-103 must have long-term follow-up for 15 years from the date of administration. During the long-term follow-up period, AEs, exploratory efficacy etc. are observed, and the observation period is every 6 months within 5 years and then yearly until 15 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center, Single-arm, Open-label Phase 1 Clinical Trial to Assess the Safety and Tolerability of YYB-103, IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell (CAR-T) in Treating Patients With Refractory or Recurrent Malignant Glioma
Actual Study Start Date : July 18, 2022
Estimated Primary Completion Date : February 28, 2024
Estimated Study Completion Date : April 30, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: IL13Rα2 targeted CAR-T Drug: YYB-103
Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.

Primary Outcome Measures :
  1. Dose Limiting Toxicity (DLT) [ Time Frame: 28 days after IP administration ]
  2. Maximum Tolerance Dose (MTD) [ Time Frame: 28 days after IP administration ]
  3. Recommended Phase 2 Dose (RP2D) [ Time Frame: 28 days after IP administration ]

Secondary Outcome Measures :
  1. Incidence of AE [ Time Frame: 3 months, up to 15 years if necessary ]
    CRS and ICANS (ASTCT) / Others (CTCAE V5.0)

  2. RCR [ Time Frame: 1 year, up to 15 years if necessary ]
    RCR formation will be checked by collecting samples at 3M, 6M, and every 6 months thereafter until 5 years from IP administration, and then will be followed up annually thereafter until 15 years from IP administration via medical history without collecting samples. If all RCR test results are negative for 1 year after IP administration, sample collection will be stopped, and annual follow-up.

  3. Pharmacokinetics and cytokine levels [ Time Frame: 3 months, up to 15 years if necessary ]
    Peripheral blood (PB) and Cerebral spinal fluid (CSF)

  4. Disease response (DCR) [ Time Frame: Baseline up to 6 months ]
    Tumor response will be assessed by comparison with baseline magnetic resonance imaging by iRANO criteria. Evaluation of DCR is the proportion of subjects with CR or PR or SD as a result of tumor response assessment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Primary inclusion criteria (Screening criteria)

    : Only subjects who meet all of the following conditions conduct examinations and tests including the IHC and PBMC

    • Provision of voluntary written consent to participate in this clinical trial
    • Male and female aged ≥ 19 years to <75 years
    • Patients with histologically or cytologically confirmed progressive malignant glioma (Grade III or IV according to the WHO criteria) and histological and/or radiologic data to confirm that it is refractory or recurrent (applicable to 'Progression Disease (PD)' according to the Response Assessment for Neuro-Oncology (RANO) criteria for high grade gliomas defined by the Society for Neuro-Oncology) despite treatment applicable to the standard treatment for each stage
    • Subject with the Karnofsky Performance Status (KPS) Scale ≥ 60
    • Subject with the life expectancy of least 12 weeks at the investigator's discretion
    • Subject who satisfies the following treatment condition, regardless of the previous line of treatment
    • At least 12 weeks after completion of the last anticancer radiation treatment
    • Other cell toxicity therapy not mentioned above: At least 3 weeks have passed
    • Non-cytotoxic agent (e.g., interferon, tamoxifen, etc.): At least 1 week has passed
    • Completion of treatment of all toxicities and AEs (other than alopecia and vitiligo) due to the previous treatment
  2. Secondary Inclusion Criteria (Eligibility Criteria)

    • Subjects confirmed as positive for IL13Rα2 expression from immunostaining (IHC)
    • Subjects with Peripheral Blood Monocyte Count ≥ 7.5x10^5 cells/5 ml from the PBMC test
    • Subjects with appropriate bone marrow, liver, and kidney function by satisfying all of the following in clinical laboratory tests

      • WBC ≥ 2,000/μl
      • ANC ≥ 1,000/μl
      • Platelet count ≥ 75,000/μl
      • Hemoglobin ≥ 8.0 g/dL
      • ALT/AST ≤ 2.5 x ULN
      • Serum creatinine ≤ 1.5 x ULN
      • Total bilirubin ≤ 1.5 x ULN

Exclusion Criteria

  1. Primary Exclusion Criteria (Screening criteria)

    • Subjects diagnosed with ventricular seeding, spinal drop metastasis, or leptomeningeal metastasis from radiologic testing obtained at screening
    • Subjects with findings of immunodeficiency, autoimmune disease (e.g.; rheumatoid arthritis, systemic lupus erythematosus, vasculitis, multiple sclerosis, etc.) or inflammatory disease
    • Subjects with significant active cardiovascular disease including the following

      • Uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg), unstable angina, pulmonary embolism, cerebrovascular disease, valvular disease, cardiac failure, or myocardial infarction or serious cardiac arrhythmia within the past 6 months
    • Subjects with a medical history of malignant tumor other than the study indication within 5 years of screening (however, within 3 years of screening in case of malignant tumor (e.g., appropriately treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ, etc.) with minimal risk of metastasis/recurrence and death)
    • Subjects who continuously used systemic immunosuppressants (including but not limited to cyclophosphamide, azathioprine, methotrexate, and thalidomide) other than steroids within 2 weeks of screening
    • Subjects on systemic steroids who received a dose exceeding dexamethasone 6 mg/day (or equivalent dose) within 1 week of screening(note that topical steroids, inhaled steroid, and use of transient steroids for prevention of vomiting prior to anticancer agents administration are acceptable)
    • Subjects with a history of previously using an immune cell therapy agent
    • Subjects with a medical history of severe allergy, anaphylaxis, or other hypersensitivity reaction to the chimeric or humanized antibody or fusion protein
    • Subjects who participated in other clinical trial (medicinal product or medical device) within 4 weeks of screening
    • Women of childbearing potential and men who have a plan to get pregnant until 3 months after investigational product administration, are not willing to practice appropriate contraception method*, or are not willing to maintain abstinence from sexual intercourse

      * Hormonal contraception method, intrauterine device (IUD) or intrauterine system (IUS), surgical sterilization of the subject or partner, tubal ligation, double barrier method (a combined use of a barrier method such as a female condom, cervical cap, contraceptive diaphragm, or contraceptive sponge with a male condom), single barrier method combined with spermicide)

    • Pregnant women or breastfeeding mothers
    • Subjects who are determined by the investigator to be ineligible as subjects of this clinical trial for other reason
  2. Secondary Exclusion Criteria (Eligibility Criteria)

    • Subjects who are positive to any of the following virus test results at screening

      • Hepatitis B virus surface antigen (HBsAg)
      • Hepatitis C virus antibody test (anti-HCV Ab)
      • HIV antibody test (anti-HIV)
    • Subjects who are determined by the investigator to be ineligible as subjects of this clinical trial for other reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05540873

Layout table for location contacts
Contact: Sungmin Jun +82262048381 smjun@cellabmed.com

Layout table for location information
Korea, Republic of
National Cancer Center, Korea Recruiting
Goyang-si, Gyeonggi, Korea, Republic of
Contact: Ho-Shin Gwak         
Contact: Jihye Yoon         
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: CellabMED
ClinicalTrials.gov Identifier: NCT05540873    
Other Study ID Numbers: CLM_103_MG001
First Posted: September 15, 2022    Key Record Dates
Last Update Posted: January 6, 2023
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CellabMED:
Chimeric antigen receptor
Malignant glioma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue